Veru announced the enrollment of the first patient in its Phase 2 study of zuclomiphene citrate for the treatment of hot flashes caused by androgen deprivation therapy, or ADT, for men with advanced prostate cancer. The double-blind, placebo-controlled, dose-finding study is designed to evaluate the safety and efficacy of daily oral zuclomiphene citrate in patients with moderate to severe hot flashes caused by ADT for advanced prostate cancer. The study, conducted at multiple U.S. sites, is designed to enroll approximately 120 patients randomized to one of four treatment arms. The primary endpoint of the study is the mean change in frequency and severity of hot flashes relative to baseline at week 4.
